Phio Pharmaceuticals CORP 8-K filings

Phio Pharmaceuticals reports positive results from the second cohort of its PH-762 clinical study, showing complete tumor clearance in two patients with cutaneous squamous cell carcinoma.

Phio Pharmaceuticals has successfully priced a registered direct offering and concurrent private placement, raising approximately $0.48 million to support working capital.

Phio Pharmaceuticals has successfully raised $1.15 million through a registered direct offering and concurrent private placement to support its cancer treatment development.

Phio Pharmaceuticals' lead compound, PH-762, demonstrated a positive safety profile in its Phase 1b clinical trial, leading to a recommendation to escalate to the next dose concentration.

Phio Pharmaceuticals announced positive results from its Phase 1b clinical trial for PH-762, along with its third quarter 2024 financial results, showing a decrease in net loss.

Phio Pharmaceuticals announced the presentation of clinical data from its Phase 1b trial at the Society for Immunotherapy of Cancer (SITC) annual meeting, showcasing positive responses in patients with cutaneous carcinomas.

Phio Pharmaceuticals announced positive safety data from its Phase 1b clinical trial, along with second quarter 2024 financial results and a business update.

Phio Pharmaceuticals has appointed Robert M. Infarinato as its new Vice President and Chief Financial Officer, effective August 1, 2024.

Phio Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement following a one-for-nine reverse stock split.

Phio Pharmaceuticals has successfully raised approximately $3.1 million by inducing warrant holders to exercise their existing warrants at a reduced price, while issuing new warrants.

Phio Pharmaceuticals has terminated its share purchase agreement with Triton Funds due to a drop in the company's stock price below the agreed purchase price.

Phio Pharmaceuticals has approved a 1-for-9 reverse stock split to increase its share price and maintain its Nasdaq listing.

Phio Pharmaceuticals Corp. has increased the number of shares available under its 2020 Long Term Incentive Plan and approved a reverse stock split at its 2024 Annual Meeting.

Phio Pharmaceuticals announced that the Safety Monitoring Committee has recommended dose escalation in the Phase 1b clinical trial of their lead compound PH-762 after a positive safety review of the initial cohort.

Phio Pharmaceuticals has entered into a purchase agreement with Triton Funds for up to $621,000 through the sale of common stock.

Phio Pharmaceuticals reported a reduced net loss for Q1 2024, driven by decreased research and development expenses, and provided an update on their Phase 1b clinical trial.

Phio Pharmaceuticals reported its 2023 year-end financial results, highlighted by progress in its PH-762 clinical trial and a strategic shift towards product development.

Phio Pharmaceuticals Corp. has been notified by Nasdaq that it is not in compliance with the minimum bid price rule, as its stock price has remained below $1.00 for 30 consecutive business days.